Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MW\DfZRwfG:6aXRCpIF{e2G7 NEn6UVc1QCCq MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NHWtNFYh|ryPLh?= NFLIcmgzOTN6OEG5NS=>
human colon cancer cell line (LoVo cells) MVLQdo9tcW[ncnH0bY9vKGG|c3H5 M{PyWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iY3;sc44h[2GwY3XyJINmdGxibHnu[UApVG:YbzDj[YxteylidYPpcochVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88UU4> NYXmOFdMOTF3OUG1NFU>
human LoVo cells NWrnXFBnWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2LuXVQ5KHSxIEeyJIg> M2DqcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;Wc{Bk\WyuczDh[pRmeiB2ODD0c{A4OiCqcoOgZpkhVVSWIHHzd4F6 NY\mbZFkOjJzOEK5Nlk>
P19 cells MkL4SpVv[3Srb36gZZN{[Xl? MmPSTY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgdoVk\XC2b4KgbY4hWDF7IHPlcIx{NCCLQ{WwQVAvODB{IN88UU4> NITibVAyPTd5MUSxPS=>
human BJ cells NGO1Tm5EgXSxdH;4bYPDqGG|c3H5 NGr5WHU4OiCq M3Ha[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTBwMECyJO69VS5? NYfLV2JGOjJ7MkGwPFE>
human HT-29 cells NUL5R|U5TnWwY4Tpc44h[XO|YYm= M{faSVIhcA>? NYnZUnNuTW[oZXP0JI9vKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFIhcHK|IIXzbY5oKEqFLUGgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHHzd4F6 NInMSW0zOTR{OEO3OS=>
human A549 cells NF\kW3hEgXSxdH;4bYPDqGG|c3H5 M1ziN|czKGh? MlfHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2R? NXj6[GFNOTh2OES3O|U>
human HT-29 cells NVP2SoFETnWwY4Tpc44h[XO|YYm= NX7WUoRkUW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCxdHXueIlidCCrbjDoeY1idiCKVD2yPUBk\WyuczD1d4lv\yCMQ{Gg[JlmKHO2YXnubY5oKGK7IH\seY9z\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYYPzZZktKEmFNUC9Nk42KG6P NUPZcZNGOjF3MUOyPVM>
human HT-29 cells MX\GeY5kfGmxbjDhd5NigQ>? NYPLO3pLOiCq MY\JcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiWLUK5JINmdGy|IHHzd4V{e2WmIILl[JVkfGmxbjDv[kBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIIDveIVvfGmjbDDh[pRmeiB{IHjyd{BjgSC3c3nu[{BLSzFic4ThbY5qdmdiYomg[ox2d3Knc3PlcoNmKGOnbHytZoF{\WRiYYPzZZktKEWFNUC9Nk43KG6PLh?= MnnnNlE6PzNzMEG=
Sf9 cells MV;GeY5kfGmxbjDhd5NigQ>? NXvJT5RGUW6qaXLpeIlwdiCxZjDoeY1idiCVeXug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0{KG6PLh?= M{DZZlE5QDJ|N{i0
human HUVEC MWPQdo9tcW[ncnH0bY9vKGG|c3H5 MoO0OFghfG9iN{KgbC=> NHvYW5lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVEKGGodHXyJFQ5KHSxIEeyJIhzeyCkeTDNWHQh[XO|YYm= M3LxWFIzOTh{OUK5
P19 cells M4TMeWZ2dmO2aX;uJIF{e2G7 Mn:wTY5pcWKrdHnvckBw\iCScn;0[YlvKEurbnHz[UBCKGmwIGCxPUBk\WyuczygTWM2OD12IH7NMi=> NF[zPWwyPTd5MUSxPS=>
Sf9 cells MlrVSpVv[3Srb36gZZN{[Xl? NUDNb4NYUW6qaXLpeIlwdiCxZjDoeY1idiCIeX6g[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjZoTldkAyKG2rbjDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGC= NHnsO|AyPzNzNUi1Ny=>
Sf21 cells Ml76SpVv[3Srb36gZZN{[Xl? Mm\iTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u NUDWOopiOTdyOEiwOVk>
human colon carcinoma cell line HCT116 M2HyNGZ2dmO2aX;uJIF{e2G7 NIr5U2tEd26lZX70doF1cW:wIILldZVqemWmIH\vdkBoem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBkd2yxbjDjZZJkcW6xbXGgZ4VtdCCuaX7lJGhEXDFzNjygTWM2OD14IH7NMi=> NF:5[3QyPTV|N{O0OS=>
human ST486 cells MnvZVJJwdGmoZYLheIlwdiCjc4PhfS=> MlvmOFghfG9iN{KgbC=> MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOWNEi2JINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9O{BvVS5? NYXNTHB{OjJzOEK5Nlk>
human MDA-MB-231 cells MUnDfZRwfG:6aXRCpIF{e2G7 NXTV[Zk2PzJiaB?= M3qwSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJibXX0bI9lNCCJSUWwQVcvOSCwTT6= M1zrZ|E5PDh2N{e1
P19 cells MnXqSpVv[3Srb36gZZN{[Xl? MV3Jcohq[mm2aX;uJI9nKEO7Y3zpck1l\XCnbnTlcpQhc2mwYYPlJFEhcW5iUEG5JINmdGy|LDDJR|UxRThibl2u MYOxOVc4OTRzOR?=
human DLD1 cells Ml3QVJJwdGmoZYLheIlwdiCjc4PhfS=> NW\MR|NFPDhvN{KgbC=> MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESOREGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25JI5ONg>? NFTYT2QzOjF6MkmyPS=>
insect cells MmGxSpVv[3Srb36gZZN{[Xl? NH\HUXFKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDpcVEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{BjgSCKVGLGMEBKSzVyPUGwJI5ONg>? M1[xfVE6OTd7MEe2
V79 MZ cells MlvlSpVv[3Srb36gZZN{[Xl? NXjNSXhVUW6qaXLpeIlwdiCxZjDoeY1idiCjbHTvd5Rmem:wZTDzfY51cGG|ZTDlfJBz\XO|ZXSgbY4hXjd7IF3aJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzkc5N1\XKxbnWgd5lvfGinc3nzMEBKSzVyPUGxJI5ONg>? M17IZlI1PDJ{NUG5
P19 cells NUXPcnRPTnWwY4Tpc44h[XO|YYm= NVHCN4NUUW6qaXLpeIlwdiCxZjDWZZNkfWyjcjDlcoRwfGinbHnhcEBoem:5dHig[oFkfG:{IILlZ4VxfG:{IHnuJHAyQSClZXzsd{whUUN3ME2xOEBvVS5? M2HZUFE2PzdzNEG5
Sf9 cells NH;Q[FZHfW6ldHnvckBie3OjeR?= NX3Od4JiOjBibXnudy=> M3LvWWlvcGmkaYTpc44hd2ZiaIXtZY4hTnmwIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNlAhdWmwczDifUBGVEmVQTDpckBxemW|ZX7j[UBw\iBzIIXtc4wwVCCDVGCsJGlEPTB;MUWgcm0v NELOZYgyPzNzNUi1Ny=>
human PBMC MVTGeY5kfGmxbjDhd5NigQ>? MYeyOEBp MYfTeZBxemW|c3nvckBw\iCLTEKgdJJw\HWldHnvckBqdiCqdX3hckBRSk2FIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRUwhUUN3ME2xOkBvVS5? NX;oN|V4OTh3OEWwOFY>
human A549 cells MULDfZRwfG:6aXRCpIF{e2G7 M2T2ZVQ5KGh? M1n4XmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9NlAhdk1w NWrhU3kxOjV6MkW5N|Q>
human CEM cells NXfjSFFFS3m2b4TvfIlkyqCjc4PhfS=> NUPmZ4FiPzJiaB?= NH;6foJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNidGOnaX6gRW0h[XO|YYmsJGlEPTB;MkOgcm0v NWHOUpF3OjJ7MkGwPFE>
human HeLa cells NEnzTWJEgXSxdH;4bYPDqGG|c3H5 NG\0NZY1QCCq M4\V[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOUBvVS5? Mkn4NlU5OjV7M{S=
human PC3 cells M2rJSmN6fG:2b4jpZ:Kh[XO|YYm= MmjZOFghcA>? NFnaSGlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w M{jWRlI2QDJ3OUO0
human SF268 cells MXTDfZRwfG:6aXRCpIF{e2G7 MXy0PEBp NUi0TohjS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z{NkigZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF01PCCwTT6= Mnn0NlE2OTN{OUS=
human MCF7 cells M3npXWN6fG:2b4jpZ:Kh[XO|YYm= M1rvZlQ5KGh? NGPWd4JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVAhdk1w MkWzNlE{QDhzOUG=
HEK293 cells MXfDfZRwfG:6aXRCpIF{e2G7 MnfBO|IhcA>? M4\oZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{R3zvJIF{e2G7LDDJR|UxRTV4IH7NMi=> NFzWSXEzPDd4M{K2Ni=>
HUE cells NInUb|lHfW6ldHnvckBie3OjeR?= NV3vT5RFQTBibXnudy=> M1XWRWlvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIFjVSUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHS{ZXH0[YQh\m:{IEmwJI1qdnNiYnXmc5JmKF[HR1[gZ4hidGynbnflJIJ6KEWOSWPBMEBKSzVyPUewJI5ONg>? NIrpTo0zODF5MEG2Ny=>
human A431 cells NF7NdJNEgXSxdH;4bYPDqGG|c3H5 MYSyOEAhcA>? MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEK0JIhzeyC3c3nu[{BCdm6neHnuJHZmTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHL5JG1VXCCjc4PhfUwhUUN3ME23NEBvVS5? M4foT|IzPTRzMEWx
human Jurkat cells MmLQVJJwdGmoZYLheIlwdiCjc4PhfS=> M33pOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTmFMOyCneIDy[ZN{cW6pIFnMNk1{fGmvdXzheIVlKGi3bXHuJGp2emujdDDj[YxteyxiSVO1NF04OSCwTT6= MXWxPVQzPzJyMx?=
HEK293 cells MorJSpVv[3Srb36gZZN{[Xl? MWfJcohq[mm2aX;uJI9nKEmOLUigdoVt\WG|ZTDifUBJTUt{OUOgZ4VtdHNiZYjwdoV{e2mwZzDQT2Mu[mW2YUKsJGlEPTB;N{egcm0v MVSxOVc4OTRzOR?=
human KE-97 cells MmDVR5l1d3SxeHnjxsBie3OjeR?= MYe3NkBp NFv3blhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMTS17NzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|IN88UU4> MkHGNlQ{Ojh{OEO=
human CHOK1 cells M3HLXmN6fG:2b4jpZ:Kh[XO|YYm= NHLxcVg1QCCq NIX4fWdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v NF23UoIzOTVzM{K5OC=>
mouse NIH/3T3 cells NWro[ZNmS3m2b4TvfIlkyqCjc4PhfS=> NEPTOHE6PiCq MmLHR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUmlJNzOWMzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u NWTVUHFZOjR|NkG1NlE>
human A2780 cells NGruU3dEgXSxdH;4bYPDqGG|c3H5 NG\PdYo6PiCq MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuNkDPxE1w MVOyOFM3OTV{MR?=
human 8505C cells MnjxR5l1d3SxeHnjxsBie3OjeR?= NYfrdJozQTZiaB?= Mk[4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gPFUxPUNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= NHvBdXQzPDN4MUWyNS=>
human 518A2 cells NFjNWJZEgXSxdH;4bYPDqGG|c3H5 M{LwNVk3KGh? NFLWe2REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> NVj5N5ZIOjR|NkG1NlE>
human HuH7 cells NHLyS4pEgXSxdH;4bYPDqGG|c3H5 NHrve5o4OiCq NX:xbWpWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> M{DZfVI1OzJ6Mkiz
FL5.12-Akt1 cells M3jWT3Bzd2yrZnXyZZRqd25iYYPzZZk> Mni3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDGUFUvOTJvQXv0NUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NE4zQSEQvF2u Mn7SNVY1ODN4Mk[=
human MiaPaCa-2 cells MWLQdo9tcW[ncnH0bY9vKGG|c3H5 NXLx[2VvSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNbYFR[UOjLUKgZ4VtdHNuIFnDOVA:OC5|NzFOwG0v M33DelE3PDF|N{iw
human BGC823 cells MX3DfZRwfG:6aXRCpIF{e2G7 NFvOe3Q4OiCq MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTy[U1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QCEQvF2u M3Ph[|I1OzJ6Mkiz
human MCF7 cells MmrCR5l1d3SxeHnjxsBie3OjeR?= NXXTV4VLQTZiaB?= MnnCR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOEDPxE1w NHPubGYzPDN4MUWyNS=>
human A549 cells MkC5R5l1d3SxeHnjxsBie3OjeR?= M3HvXlk3KGh? MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD62JO69VS5? NYTtepVkOjR|NkG1NlE>
HEK293 cells M4TDb2N6fG:2b4jpZ:Kh[XO|YYm= NXrsNYM2S3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? MoDyNlU{OTZ|MUe=
human Raji cells  NXHZZoZpS3m2b4TvfIlkyqCjc4PhfS=> NFjvbJJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBT[WqrIHPlcIx{NCCHQ{WwQVIh|ryPLh?= NV;BOplZOjV|MU[zNVc>
human HepG2 cells MoP0R5l1d3SxeHnjxsBie3OjeR?= NFnITYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyxiRVO1NF0zKM7:TT6= NHvoWHAzPTNzNkOxOy=>
human BJ cells NYX1cpdvS3m2b4TvfIlkyqCjc4PhfS=> MofPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmoh[2WubIOsJGVEPTB;MjFOwG0v NFXBZVEzPTNzNkOxOy=>
human U937 cells NWHkcZRRS3m2b4TvfIlkyqCjc4PhfS=> NUDTPZc1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTl|NzDj[YxteyxiSVO1NF0zKM7:TT6= MUSxO|A5QDB4Nx?=

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00082017 Completed Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 2004 Phase 2
NCT00072267 Completed Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer University Health Network, Toronto|National Cancer Institute (NCI) January 2004 Phase 2
NCT00072189 Terminated Recurrent Melanoma|Stage IV Melanoma National Cancer Institute (NCI) November 2003 Phase 2
NCT00030888 Unknown status Kidney Cancer University of California, San Francisco|National Cancer Institute (NCI) December 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID